Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
General13 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News22 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News15 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General24 hours agoIndigenous excellence honoured in NAIDOC’s 50th year